Benitec Biopharma Limited (BLT) Is Yet to See Trading Action on Mar 15

March 15, 2018 - By Peter Erickson

Shares of Benitec Biopharma Limited (ASX:BLT) closed at 0.19 yesterday. Benitec Biopharma Limited currently has a total float of 205.14 million shares and on average sees 243,192 shares exchange hands each day. The stock now has a 52-week low of 0.12 and high of 0.34.

Australia: Things You Didn’t Know About S&P/ASX 200 Index

S&P ASX 200 is one of Australia’s oldest and leading market index for stocks. The index contains the country’s top 200 companies ranked by way of float-adjusted market capitalization. The index came into being in the early 2,000’s after replacing the All Ordinaries that was the primary investment benchmark in the 1990’s.

Value Changes

Value changes in the index are measured with respect to changes in stock prices rather than market capitalization as is the case in other global market indexes. What this means is that the index value can only change, depending on stock prices changes rather than market capitalization.

Taking into consideration historical data from when the index operated as ‘All Ordinaries’, ASX 200 boasts of an all-time low of 1,538.50 points, registered in November 1992. The index highest point was recorded in November 2007, having climbed to highs of 6,000, from 3,133.3 points at the time of inception in April 2000.

Investors can still be able to look for data beyond 2000 even though the index came to be in the early 2000’s.

Listing Requirement

All the 200 companies listed in the ASX 200 have their shares listed on the country’s bourse the ASX; considered as one of the main requirements. Another factor that is usually taken into consideration prior to the listing into the index is a stock’s liquidity levels. Benitec Biopharma Limited has interesting liquidity profile. A company should be liquid enough to support huge volume trades as well as unusual price changes. Benitec Biopharma Limited has interesting liquidity profile.

While the maximum number of stocks that the index can carry in any given quarter is 200, the same can also be reduced with the exclusions of stocks that do not meet the minimum requirement. The last rebalancing was carried out on September 16, 2016 with the next one slated for December 16, 2016. In the just concluded rebalancing, six companies were dropped paving the way for the inclusion of six others that had met the minimum requirements.

Benitec Biopharma Limited is a company traded on the ASX. Gaining accreditation for listing in the index is always a positive for companies given that the popularity that comes with the same goes a long way in enticing investment as well as research from stock broking firms and analysts.

Stocks listed in the index come from a wide range of sectors ranging from utility financials to healthcare. Currently, companies with exposure to the financial sector account for 10% of the ASX 200 weighted points. These companies also account for nearly 80% of ASX total equity capitalization.

Index Performance

The index is currently trading at highs of 5300 points having rallied by 4.71% since the start of the year. The impressive run comes on institutional investors both local and international flocking the country’s equity market in a bid to advantage of a bull run in play. It is interesting how this will affect Benitec Biopharma Limited. Low interest environment is also fuelling interest in Australia’s stocks give that the same goes a long way to guarantee higher returns on invested funds. Benitec Biopharma Limited liquidity position heated the attention of numerous investors from abroad.

Strong governance structure is one of the key reasons why investors are rushing to invest I the country’s market further helping push the index even higher. Australia is currently raked top in Asia I terms of corporate governance.

More notable recent Benitec Biopharma Limited (ASX:BLT) news were published by: which released: “Benitec Biopharma Ltd. Wt” on August 08, 2017, also with their article: “Benitec Biopharma Ltd. ADR BNTC (US: Nasdaq)” published on July 31, 2015, published: “Benitec Biopharma reports financial results for the 2018 fiscal second quarter …” on February 22, 2018. More interesting news about Benitec Biopharma Limited (ASX:BLT) were released by: and their article: “Benitec Biopharma advances OPMD orphan disease program” published on August 08, 2017 as well as‘s news article titled: “Benitec Biopharma makes significant progress in ocular program” with publication date: February 02, 2017.

Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference in Australia and the United States. The company has market cap of $38.98 million. The firm provides BB-301, a single administration ddRNAi gene therapy for the treatment of oculopharyngeal muscular dystrophy; BB-201, a ddRNAi therapy for the treatment of wet age-related macular degeneration; and BB-101 and BB-103 ddRNAi therapies for the treatment of human hepatitis B. It currently has negative earnings. It also offers BB-401 and BB-501 for the treatment of oncology.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.